Barron’s

The Merger Fund’s (MERFX) underlying strategy and average annual return is cited in the Barron’s piece, “Liquid Alternatives: Looking Beyond Stocks and Bonds.”

Barron’s

As Bristol-Myers Squibb – Celgene remains one of the most highly anticipated deals of 2019, Westchester Capital Management’s Roy Behren explains why he believes it will get approval from the ISS in Avi Salzman’s Barron’s article, “Bristol-Myers/Celgene Deal Is About to Face a Crucial Test.”

Read Full Article